Nipah vaccine (Janssen Vaccines/University of Oxford)

The ultimate vaccine against infections caused by Nipah virus should be capable of providing protection at the respiratory tract-the most probable port of entry for this pathogen.Intranasally delivered vaccines, which target nasal-associated lymphoid tissue and induce both systemic and mucosal immunity, are attractive candidates for enabling effective vaccination against this lethal disease.Herein, the water-soluble polyphosphazene delivery vehicle assembles into nanoscale supramol. constructs with the soluble extracellular portion of the Hendra virus attachment glycoprotein-a promising subunit vaccine antigen against both Nipah and Hendra viruses.These supramol. constructs signal through Toll-like receptor 7/8 and promote binding interactions with mucin-an important feature of effective mucosal adjuvants.High mass contrast of phosphorus-nitrogen backbone of the polymer enables a successful visualization of nanoconstructs in their vitrified state by cryogenic electron microscopy.Here, we characterize the self-assembly of polyphosphazene macromol. with biol. relevant ligands by asym. flow field flow fractionation, dynamic light scattering, fluorescence spectrophotometry, and turbidimetric titration methods.Furthermore, a polyphosphazene-enabled intranasal Nipah vaccine candidate demonstrates the ability to induce immune responses in hamsters and shows superiority in inducing total IgG and neutralizing antibodies when benchmarked against the resp. clin. stage alum adjuvanted vaccine.The results highlight the potential of polyphosphazene-enabled nanoassemblies in the development of intranasal vaccines.